Capital Markets Day

Poolbeg Pharma

17/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221117:nRSQ6932Ga&default-theme=true

RNS Number : 6932G  Poolbeg Pharma PLC  17 November 2022

Poolbeg Pharma Plc

 

Capital Markets Day

 

17 November 2022 - Poolbeg Pharma (http://www.poolbegpharma.com/) (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease
pharmaceutical company with a unique capital light clinical model, announces
that it will be holding a Capital Markets Day for analysts and institutional
investors on Wednesday 30 November between 10am - 12:45pm.

 

The event, which will be chaired by Jeremy Skillington, Chief Executive
Officer, will provide insights into a number of the Company's growing pipeline
of infectious disease vaccines and treatments and one of its innovative
artificial intelligence programmes which is unlocking the power of human
challenge trial data. In addition, attendees will gain a greater understanding
of how Poolbeg's unique model and business development strategy can drive
growth from the infectious disease market. A networking lunch will follow at
the end of the session.

 

There will be an opportunity for attendees to take part in a Q&A with
Poolbeg's management team including Ian O'Connell, Chief Financial Officer and
David English, VP of Business Development as well as a number of guest
speakers:

 

 •    Dr Tal Almog of CytoReason, one of Poolbeg's artificial intelligence partners;
      a world leader in AI which to date has worked with five of the world's top ten
      pharma companies
 •    Derek Gilroy, Head of the Centre for Clinical Pharmacology and Professor of
      Immunology at University College London and has pioneered research examining
      the molecular and biochemical pathways that regulates the resolution of acute
      immune reactions
 •    Professor Brendan Buckley, co-founder of Minerva Medical, acquired by IQVIA
      and Firecrest Clinical, acquired by ICON plc where he held the position of
      Chief Medical Officer. Brendan has over thirty years of experience in clinical
      research and has published over 150 scientific papers
 •    Further speakers will be announced in advance of the event

 

Analysts, institutional investors and media are welcome to attend the event in
the City of London. Due to restrictions on numbers, it will not be possible
for all interested parties to attend in-person. However, a live webcast will
be available for retail investors and others to view the presentations here
(https://stream.brrmedia.co.uk/broadcast/636e29ab0f83362af109fc68) .

 

To register your interest to attend the in-person event, please RSVP to
poolbeg@instinctif.com (mailto:poolbeg@instinctif.com) .

 

A recording of the presentation will be made available on the Company's
website after the event here
(https://www.poolbegpharma.com/investors/events-presentations/) .

 

- Ends -

Enquiries

 Poolbeg Pharma Plc                                  +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 finnCap Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson

Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)               +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                             +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Instinctif Partners                                 +44 (0) 20 7457 2020

 Melanie Toyne Sewell, Rozi Morris, Tim Field        poolbeg@instinctif.com (mailto:poolbeg@instinctif.com)

 

About Poolbeg Pharma

 

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company,
with a capital light clinical model which aims to develop multiple products
faster and more cost effectively than the conventional biotech model. The
Company, headquartered in London, is led by a team with a track record of
creation and delivery of shareholder value and aspires to become a "one-stop
shop" for Big Pharma seeking mid-stage products to license or acquire.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025.

 

With its initial assets from hVIVO plc (http://www.hvivo.com) (formerly named
Open Orphan plc), an industry leading infectious disease and human challenge
trials business, Poolbeg has access to knowledge, experience, and clinical
data from over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage products,
reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has
a small molecule immunomodulator for severe influenza (POLB 001) which has
commenced its LPS human challenge trial with initial results expected by year
end 2022; a first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine candidate for
Melioidosis (POLB 003). The Company is also developing an oral vaccine
delivery platform and is progressing two artificial intelligence (AI)
programmes to accelerate the power of its human challenge model data and
biobank, with outputs from the first programme expected by year end 2022.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com) or follow us on Twitter
(https://twitter.com/PoolbegPharma) and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/) @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZMMMMVDGZZZ